Investor profile

Versant Ventures

Venture Capital · Founded 1999 · San Francisco, United States

Global healthcare investment firm

172 portfolio companies Venture Capital · $12B invested · 339 investments · Investor rank #219 · Last investment 11/2025

Portfolio companies 172 ↑ 19% 5y

Decacorns 3

Thoroughbreds 12

Power Law #345Investor Ranking · Global · 2026 · Top 2%

Featured in

News Kurma Partners closes €215M Biofund IV, crosses €1B in assets under management Apr 23, 2026

Exits

Versant Ventures’ biggest exits.

Portfolio companies that IPO’d or were acquired at $1B+, with the valuation recorded at exit and — for those still public — their value today. Exit events come from each company’s funding-round history; entry stage from Versant Ventures’ transaction record.

Jazz Pharmaceuticals

$108M IPO · 2007

Entered Series ANow $19BHealth

Insulet

IPO · 2007

Entered Series B+Now $12BHealth

Crinetics Pharmaceuticals

$391M IPO · 2018

Entered Series ANow $10BHealth

Glaukos

$415M IPO · 2015

Entered Series ANow $9.8BHealth

Inari Medical

$1.0B IPO · 2020

Entered Series ANow $4.9BHealth

Ambrx

$4.7B IPO · 2021

Entered Series B+Now $1.6BHealth

Veracyte

$65M IPO · 2013

Entered Series B+Now $4.4BHealth

Akero Therapeutics

$433M IPO · 2019

Entered Series ANow $3.8BHealth

RayzeBio

$311M IPO · 2023

Entered Series ANow $3.7BHealth

OLO

$3.5B IPO · 2021

Entered Series B+Now $1.4BFood

CymaBay Therapeutics

IPO · 2014

Entered Series B+Now $3.5BHealth

CRISPR Therapeutics

$626M IPO · 2016

Entered Series ANow $3.1BHealth

Portfolio analysis

Where Versant Ventures’ portfolio is concentrated.

Distribution of portfolio companies by headquarters country, sector, entry stage and current growth stage. Across all 172 portfolio companies. "Stage entered" is the first priced round the investor joined, derived from the investor’s transaction history.

By countryCount

USA150
Switzerland12
Canada3
France2
Cuba1
Denmark1
Ireland1
Netherlands1
UK1

By sectorCount

Health157
Home Living4
Fashion2
Wellness Beauty2
Energy1
Enterprise Software1
Fintech1
Food1
Hosting1
Real Estate1
Security1
Semiconductors1

By stage enteredCount

Series A99
Series B+68
Seed5

By growth stageCount

Late Growth80
Breakout Stage76
Early Growth13
Mature3

Portfolio market map

Inside Versant Ventures’ portfolio.

The 60 highest-funded portfolio companies, of 172 tracked.

Century Therapeutics

Health

$308M

Crinetics Pharmaceuticals

Vividion Therapeutics

Bright Peak Therapeutics

BlueRock Therapeutics

Health · Unicorn

$1.0B

Monte Rosa Therapeutics

Black Diamond Therapeutics

VenatoRx Pharmaceuticals

Capsida Biotherapeutics

Audentes Therapeutics

Belharra Therapeutics

Alexza Pharmaceuticals

Oyster Point Pharmaceuticals

Portfolio founders

Where Versant Ventures’ portfolio founders come from.

106 founders across the 100 highest-funded portfolio companies — by current location, university attended, and the companies they worked at before founding. Sourced from the founder records the API links to each portfolio company.

LocationCount

United States74
Canada8
Switzerland8
Denmark5
United Kingdom3
France2
Germany1
Ireland1
Italy1
Netherlands1

UniversityCount

Massachusetts Institute of Technology7
Harvard University6
Stanford University5
University of California, Berkeley5
University of Copenhagen4
McGill University3
Simon Fraser University3
Yale University3
Harvard Business School2
King's College London2

Previous companyCount

Alantos Pharmaceuticals7
Genentech4
Harvard University3
Massachusetts Institute of Technology3
Merck & Co.3
Abbott2
Amira Pharmaceuticals2
Bristol-Myers Squibb2
Broad Institute2
Editas Medicine2

How Versant Ventures stacks up

Similar investors.

Peers the API surfaces as most similar by portfolio shape, with Dealroom investor rank and portfolio scale.

NEA

Venture Capital · Menlo Park

#36 rank 1,186 companies $2.5T portfolio

Corporate · San Francisco

#73 rank 422 companies $913B portfolio

HTGF

Venture Capital · Bonn

#675 rank 578 companies $28B portfolio

Fidelity Investments

Private Equity · Boston

#7 rank 362 companies $6.1T portfolio

Khosla Ventures

Venture Capital · Menlo Park

#53 rank 854 companies $1.9T portfolio

MassChallenge

Accelerator · Boston

#10,929 rank 1,065 companies $20B portfolio

Bpifrance

Sovereign Wealth Fund · Maisons-Alfort

#92 rank 1,363 companies $165B portfolio

Eurazeo

Private Equity · Paris

#98 rank 374 companies $158B portfolio

Key people

Key people at Versant Ventures.

Source: Dealroom next-gen API — investor team endpoint.

Figures on this page are sourced live from the Dealroom next-gen API, joined with Dealroom’s cap-table dataset (estimated holdings) and the Power Law Investor Ranking. News in “Featured in” is drawn from Dealroom’s own coverage — the stories that name this investor, not only those it is the subject of. Market sentiment is omitted until the API exposes it.